Vivus Shares SURGING and 4 Hot Stocks Making Headlines Now

Rovi Corporation (NASDAQ:ROVI) is a provider of digital entertainment guides and has fallen more since its IPO in 1997 than ever following the cut of its annual sales forecast in the midst of delays in adding new patent licensees. The company fell 38 percent to $11.01 at 9:54 a.m. ET, after falling 42 percent for its biggest drop since its IPO. The shares have fallen 28 percent so far this year as of yesterday. Shares of Rovi Corporation are trading 40.40% lower today.

VIVUS, Inc. (NASDAQ:VVUS) shares rally yet again, which continues their large surge this year, as investors celebrate the FDA approval of the company’s weight-loss drug Qsymia. Shares of VIVUS, Inc. are trading 14.32% higher today.

Don’t Miss: Vivus BREAKTHROUGH Opens Up the Obesity Market.

Alkermes Plc (NASDAQ:ALKS): Wednesday, Jefferies & Company maintained its Buy rating and $24 price target on the company, according to a report published Wednesday. Shares of Alkermes Plc are trading 3.36% higher today.

Vanguard Large-Cap ETF (NYSEARCA:VV): In order to identify the best and avoid the worst ETFs and mutual funds under the large-cap growth style, investors should gain a predictive rating based on (1) stocks ratings of the holdings and (2) the all-in expenses of each ETF and mutual fund. Investors do not need to rely on backward looking ratings. One of the Attractive-or-better rated ETFs or mutual funds should be bought by investors wanting exposure to the large-cap growth style. Shares of Vanguard Large-Cap ETF are trading 0.85% higher today.

Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) protected the market exclusivity for its treatment for insomnia until 2020 by settling patent lawsuits with both Mylan Pharmaceuticals and Par Pharmaceutical Cos Inc. Shares of Somaxon Pharmaceuticals, Inc. are trading 70.0% higher today.

Don’t Miss: Vivus VIVACIOUS! Second U.S. Diet Drug Approved in 13 Years.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.